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Background: Non-muscle invasive (NMI) bladder cancer is characterised by increased expression and activating mutations of
FGFR3. We have previously investigated the role of microRNAs in bladder cancer and have shown that FGFR3 is a target of
miR-100. In this study, we investigated the effects of hypoxia on miR-100 and FGFR3 expression, and the link between miR-100 and
FGFR3 in hypoxia.
Methods: Bladder cancer cell lines were exposed to normoxic or hypoxic conditions and examined for the expression of FGFR3
by quantitative PCR (qPCR) and western blotting, and miR-100 by qPCR. The effect of FGFR3 and miR-100 on cell viability in two-
dimensional (2-D) and three-dimensional (3-D) was examined by transfecting siRNA or mimic-100, respectively.
Results: In NMI bladder cancer cell lines, FGFR3 expression was induced by hypoxia in a transcriptional and HIF-1a-dependent
manner. Increased FGFR3 was also in part dependent on miR-100 levels, which decreased in hypoxia. Knockdown of FGFR3 led to
a decrease in phosphorylation of the downstream kinases mitogen-activated protein kinase (MAPK) and protein kinase B (PKB),
which was more pronounced under hypoxic conditions. Furthermore, transfection of mimic-100 also decreased phosphorylation of
MAPK and PKB. Finally, knocking down FGFR3 profoundly decreased 2-D and 3-D cell growth, whereas introduction of mimic-100
decreased 3-D growth of cells.
Conclusion: Hypoxia, in part via suppression of miR-100, induces FGFR3 expression in bladder cancer, both of which have an
important role in maintaining cell viability under conditions of stress.
Bladder cancer is the 9th most prevalent cancer in the world (Ploeg
et al, 2009). In the United Kingdom, there are B10 000 new cases
of bladder cancer diagnosed each year. The majority (90%) of cases
of bladder cancer are derived from the urothelium and are termed
urothelial cancers (UC; Luis et al, 2007; Office for National
Statistics, 2009). There are two subtypes of UC (Wu, 2005;
McConkey et al, 2010). Around 20% of patients present with
muscle invasive (MI) cancer associated with higher mortality
(McConkey et al, 2010). However, the majority of patients
(70–80%) are diagnosed with low-grade non-muscle invasive
(NMI) disease. The NMI cancer is associated with a low incidence
of progression but a high recurrence rate (McConkey et al, 2010;
Pollard et al, 2010). Thus, although not fatal, NMI cancer requires
long-term monitoring of patients and regular surveillance, making
this the most expensive cancer per patient to manage.
The two subtypes of UC have distinct underlying aetiologies.
The MI cancer is associated with inactivating mutations in the
TP53, RB and PTEN genes (Castillo-Martin et al, 2010; Goebell and
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Knowles, 2010). In contrast, NMI cancer is characterised by
increased expression and activating mutations of FGFR3, H-RAS
and phosphotidylinositol-3-kinase (PI3K; Castillo-Martin et al,
2010; Pollard et al, 2010). FGFR3 in particular has an important
role in the pathogenesis of bladder cancer, either by mutation in
NMI cancer or by increased expression in invasive bladder cancer
(Tomlinson et al, 2007). It is one of four members of the FGFR
family of receptor tyrosine kinases that serve as cell surface
receptors for the FGF ligands. Signalling by the FGFRs leads to the
activation of multiple intracellular signalling pathways including the
extracellular signalling-regulated kinase/mitogen-activated protein
kinase (ERK/MAPK) cascade and PI3K signalling (L’Hote and
Knowles, 2005). Germline gain-of-function mutations in FGFR3
that either allow the receptor to signal in the absence of ligand or
enhance signalling upon ligand stimulation are associated with
achondroplasia and hypochondroplasia (L’Hote and Knowles,
2005). On the other hand, germline loss-of-function mutations
have been associated with CATSHL syndrome and characterised by
tall stature and loss of hearing (Toydemir et al, 2006). In addition to
bladder cancer, FGFR3 mutations have also been identified in
myeloma (Foldynova-Trantirkova et al, 2012) and cervical cancer
(Dai et al, 2001), with aberrant fusion proteins being described in
glioblastoma multiforme (Singh et al, 2012). Small molecule
inhibitors (Lamont et al, 2011) and blocking antibodies
(Martinez-Torrecuadrada et al, 2005) against FGFR3 inhibit the
growth of bladder cancer cell lines in vitro and xenografts in vivo.
Hypoxia is a key feature of many solid tumours including
bladder cancer (Turner et al, 2002; Ioachim et al, 2006; Ord et al,
2007; Chai et al, 2008; Tickoo et al, 2011). The cellular effects of
hypoxia are primarily mediated by hypoxia inducible factor (HIF),
a heterodimer of one of two possible a-subunits (HIF-1a or
HIF-2a) and a b-subunit. In normoxia, the a-subunits are
hydroxylated by prolyl hydroxylases (PHDs), which targets them
for ubiquitination and degradation. In hypoxia, the activity of the
PHDs is inhibited, leading to the stabilisation of the a-subunit and
its dimerisation with the b-subunit. The HIF transcription factor
binds to HIF response elements (HREs) on DNA to drive the
expression of target genes that regulate diverse biological processes
including angiogenesis (VEGF), metabolism (LDHA) and invasion
(LOX; Brahimi-Horn and Pouyssegur, 2009).
An emerging class of molecules whose expression is regulated by
hypoxia are microRNAs (miRNAs). MicroRNAs are small, single-
stranded RNA molecules that bind with imperfect complementar-
ity to the 30 untranslated region (UTR) of target genes and
primarily suppress the translation of the cognate protein (Pillai
et al, 2007). By expression profiling, we have previously identified a
number of miRNAs differentially regulated in distinct UC subtypes
(Catto et al, 2009). It has also been shown that miRNA expression
may predict tumour grade and therefore recurrence or progression
(Gottardo et al, 2007; Catto et al, 2009; Neely et al, 2010).
Although FGFR3 can be mutated or overexpressed in UC, the
mechanisms underlying altered FGFR3 expression in NMI bladder
cancer are not well understood. We have previously shown that
miR-100 is downregulated in NMI bladder cancer and that this
may be responsible for increased FGFR3 expression (Catto et al,
2009). In this study, we investigated the effect of hypoxia on
regulating the expression of FGFR3 and uncovered a role for both
HIF-1a and miR-100 in regulating FGFR3 levels and downstream
signalling pathways.
MATERIALS AND METHODS
Cell culture. Cell lines RT4, RT112 and T24 were obtained from
Cancer Research UK Cell Services (Clare Hall Laboratories,
London, UK). The 97-7 mutant S249C FGFR3 cell line was
obtained from Margaret Knowles, The University of Leeds, UK.
Cell lines were grown in appropriate media, containing antibiotics,
with supplemental material from Sigma-Aldrich (Dorset, UK).
Exposure of cell cultures to hypoxia (1% or 0.1% oxygen (O2)) was
undertaken in a hypoxia incubator (MiniGalaxy A, RS Biotech,
Scotland, UK) or in a hypoxic workstation (In Vivo2, Ruskinn
Technology, Bridgend, UK) in parallel with cells maintained in
normoxic conditions (5% CO2, 37 1C, 21% O2).
RNA extraction. Cells were lysed with Tri Reagent (Sigma-Aldrich)
and extracted using chloroform, followed by ethanol precipitation.
RNA quality and quantity were confirmed using the NanoDrop ND-
1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA).
Reverse transcription and qPCR for miRNAs. Hsa-miRNA
expression was assessed by real-time PCR according to the
TaqMan MicroRNA Assay protocol (Applied Biosystems,
Warrington, UK). The cDNA was synthesised from 350 ng of
total RNA using either TaqMan miRNA-specific primers and the
TaqMan MicroRNA Reverse Transcription Kit or TaqMan
Megaplex Primer Pool A, together with the TaqMan Reverse
Transcription Kit. Quantitative real-time PCR was performed on
either on the Rotor-Gene 3000 (Corbett Research, Qiagen, West
Sussex, UK) or 7900HT Fast Real Time PCR System (Applied
Biosystems). For each miRNA, each sample was assayed in
triplicate. Fold changes in miR-100 expression between treatments
and controls were determined by the 2-DDCt method (Livak and
Schmittgen, 2001), normalising the results as appropriate, using
some or all of the small nRNAs RNU44 and RNU48.
Reverse transcription and qPCR for mRNA. Total RNA was
reverse transcribed to cDNA using random primers and the High
Capacity cDNA Synthesis Kit (Applied Biosystems). The expression
of FGFR3 and CAIX along with the internal control gene ACTIN
was assayed by quantitative PCR (qPCR) using Sybr Green (Bioline
Reagents Ltd, London, UK). Primer sequences are as follows:
ACTIN_F: 50-ATTGGCAATGAGCGGTTC-30, ACTIN_R: 50-GGA
TGCCACAGGACTCCAT-30, CAIX_F: 50-CTTGGAAGAAATC
GCTGAGG-30, CAIX_R: 50-TGGAAGTAGCGGCTGAAGTC-30,
FGFR3_F: 50-GCCTCCTCGGAGTCCTTG-30, FGFR3_R: 50-CGA
AGACCAACTGCTCGTG-30.
SiRNA/miRNA mimic and anti-miR transfection protocol.
Cells were reverse transfected with the Oligofectamine transfection
reagent (Invitrogen, Paisley, UK) according the manufacturer’s
instructions. Briefly, complexes were made in OptiMEM (Invitro-
gen) with 6 ml of oligofectamine and 20 nM final concentration of
siRNA, mimics or anti-miRs. Cells were plated in full media
without antibiotics at a density of 3 105 cells per 6-cm dish to
which the complexes were added. The following day, the media
was changed and the cells treated as appropriate. The pooled
siGENOME siRNA against FGFR3, pooled siRNA control, miRNA
mimics and anti-miRs and appropriate controls were all purchased
from Dharmacon (Lafayette, CO, USA). The siRNA sequence
against HIF-1a and HIF-2a are as follows: siHIF-1a: 50-UCAA
GUUGCUGGUCAUCAG-30, siHIF-2a: 50-UAACGACCUGAAG
AUUGAA-30.
Western blot. Protein lysates were prepared in the urea lysis
buffer (6.2 M urea, 5mM DTT, 1% SDS, 10% glycerol) with added
protease (Roche, Indianapolis, IN, USA) and phosphatase (Sigma-
Aldrich) inhibitors. Lysates were quantified using the Bio-Rad Dc
System (Bio-Rad, Hertfordshire, UK). Proteins were separated on
standard SDS–polyacrylamide gels, transferred onto PVDF mem-
branes and incubated with primary antibodies overnight at 4 1C.
Antibodies against FGFR3, phospho-Thr202/Tyr204-MAPK, phos-
pho-Ser473-protein kinase B (PKB), total MAPK and total PKB
antibodies were all purchased from Cell Signaling Technologies
(Danvers, MA, USA). The antibody against ACTIN was purchased
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from Sigma-Aldrich. The HRP-conjugated secondary antibodies
were purchased from Dako (Cambridgeshire, UK) and incubated
for 1 h at room temperature. All antibodies were used at a dilution
of 1 : 1000. ECL (GE Healthcare, Uppsala, Sweden) was used and
the signal was visualised by exposing to film. Where required,
membranes were stripped with the Pierce Stripping Buffer
(Thermo Scientific, Rockford, IL, USA) before being reprobed
with a new antibody.
Correlation of miR-100 with tumour hypoxia in vivo. We have
previously generated an in vivo hypoxia gene expression metagene
signature in breast cancer; the median expression of this signature
significantly correlated with tumour hypoxia (Winter et al, 2007;
Buffa et al, 2010). MicroRNAs expression profiling has also been
performed on these tumour samples (Buffa et al, 2011). The
correlation of miR-100 expression to the hypoxia score of the
tumours was assessed by Spearmann correlation.
Luciferase assays. Genomic region (1.7 kb) immediately upstream
of the transcription start site of the human FGFR3 gene was cloned
upstream of luciferase in the pGL3-basic backbone (Promega,
Southhampton, UK). The Renilla luciferase vector pRL-TK
(Promega) was used as a transfection control. Transfection of
RT112 cells was performed using Fugene HD (Promega),
according to the manufacturers’ instructions. Cells were exposed
to normoxia, 0.1% O2 or normoxia and treated with 1mM
dimethyloxalylglycine (DMOG; Sigma-Aldrich) for 24 h. Cells were
lysed and assayed for luminescence with the Dual Luciferase
Reporter Assay System (Promega).
Cellular proliferation assays. For two-dimensional (2-D) growth
assays, cells were reverse transfected with the indicated reagents.
The following day, cells were harvested and plated at a density of
1500 cells per well of a 96-well tissue culture plate. The cells were
allowed to adhere for 24 h and then placed in either normoxia or
0.1% O2 for further 48 h. Cell viability was assessed with the
sulphorhodamine assay (Houghton et al, 2007). For each
transfection, data from five wells was taken.
For three-dimensional (3-D) growth assays, cells were reverse
transfected with the indicated reagents. The following day, cells
were harvested and plated at a density of 5000 cells per well of a
96-well ultra-low attachment plate (Corning, Amsterdam, The
Netherlands), pelleted by centrifugation and allowed to grow as
spheroids in normoxia for the indicated time. Spheroid volumes
were calculated by extrapolation from their radii. For each
transfection, data from 10 wells was taken.
Statistical analyses. Unless otherwise noted, all statistical analyses
were performed with the unpaired Student’s t-test.
RESULTS
Hypoxia induces FGFR3 expression in NMI bladder cancer cell
lines. The expression of FGFR3 was first investigated in four
bladder cell lines after exposure to hypoxia. Three cell lines, RT4,
RT112 and 97-7, were derived from low-grade bladder cancer
whereas the third cell line, T24, was derived from a grade-3 highly
malignant bladder cancer. The specificity of the antibody was
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Figure 1. Regulation of FGFR3 expression by hypoxia. (A) Expression of FGFR3 at the protein level in the bladder cancer cell lines RT4, RT112,
T24 and 97-7. Cells were cultured in normoxia (N) or 0.1% O2 (H) for 24 h and whole cell lysates were probed for FGFR3, HIF-a (RT4 and 97-7:
HIF-1a; RT112 and T24: HIF-2a) and ACTB. Quantification of representative western blots are shown. (B–D) Expression of FGFR3 mRNA in (B) RT4,
(C) RT112 and (D) 97-7 cells after exposure to normoxia (white bars) or 0.1% O2 (black bars) for the indicated time. (A) is representative of at least
three independent experiments, (B–D) are mean and s.e.m. of three independent experiments. *Po0.05, **Po0.01, ***Po0.001.
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validated by performing western blot analyses after siRNA
knockdown of FGFR3. The antibody was found to cross-react to
a number of bands with molecular weights ranging from 120 to
150 kDa (Supplementary Figure 1); these are most likely to
be alternative spliced products of the FGFR3 transcript
(Martinez-Torrecuadrada et al, 2005), although post-translational
modification is also possible. In both RT4 and RT112 cells,
increased expression of FGFR3 protein was observed after
exposure to 24 h in hypoxia (Figure 1A). In 97-7 cells, FGFR3
was expressed in both normoxic and hypoxic conditions but
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Figure 2. Mechanism of regulation of FGFR3 in hypoxia. (A) RT4 and (B) RT112 cells were cultured in normoxia (N), 0.1% O2 (H) or in normoxia and
treated with DMOG for 24 h, and whole cell lysates were probed for FGFR3, HIF-1a and ACTB. Quantification of representative western blots are
shown. (C) Expression of FGFR3 mRNA in RT4 cells cultured in normoxia (N), 0.1% O2 (H) or in normoxia and treated with DMOG for 24 h.
(D) Expression of FGFR3 protein in RT4 cells cultured in normoxia (N) or 0.1% O2 (H) for 24 h after transfection with scramble (Scr) siRNA or siRNA
against HIF-1a or HIF-2a. Quantification of a representative western blot is shown. (E) Expression of FGFR3 protein in RT4 cells cultured in
normoxia (N) or 0.1% O2 (H) and treated with the transcription inhibitor actinomycin D (ActD). Quantification of a representative western blot is
shown. (F) Luciferase induction from an FGFR3 promoter reporter construct transfected into RT112 cells cultured for 24 h in normoxia (N), 0.1% O2
(H) or in normoxia and treated with 1mM DMOG. (A and D) data are representative of two independent experiments, (B and E) data are
representative of one experiment, (C and F). Data are mean and s.e.m. of the mean of three independent experiments. *Po0.05, **Po0.01,
***Po0.001.
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further induction in hypoxia was not seen. In contrast, no
expression of FGFR3 was detectable in T24 cells (Figure 1A). The
induction of FGFR3 was also reflected at the mRNA level, where
expression levels were induced in RT4 and RT112 but not in 97-7
cells at both 24 and 48 h (Figures 1B–D). The stabilisation of HIF
by hypoxia was observed at the protein level (Figure 1A) and was
also confirmed by the induction of the robust HIF-1a target gene
CAIX (Supplementary Figures 2A–D).
To further confirm the hypoxic induction of FGFR3 expression,
RT4 and RT112 cells were treated with DMOG, a PHD inhibitor,
in normoxia. Inhibiting PHD activity led to an increase in HIF
protein levels in normoxia in both RT4 and RT112 cells (Figures
2A and B). Concomitant with this stabilisation of HIF, increased
levels of FGFR3 protein were observed in both cell lines (Figures
2A and B). In RT4 cells, this increase at the protein level was
accompanied by a concomitant increase in FGFR3 mRNA levels
(Figure 2C). We next sought to determine the HIF dependence of
FGFR3 expression. Knocking down HIF-1a but not HIF-2a
expression significantly decreased FGFR3 mRNA (Supplementary
Figure 3) and protein (Figure 2D) after exposure of RT4 cells to
hypoxia. Furthermore, treatment of these cells with the transcrip-
tion inhibitor actinomycin D also prevented the induction of
FGFR3 protein levels in hypoxia (Figure 2E).
Using MatInspector (Cartharius et al, 2005) to search for
putative HREs within the promoter region of FGFR3, two
canonical RCGTG motifs were identified. However, these were
not enriched when chromatin immunoprecipitations were per-
formed with HIF-1a (data not shown). Next, 1.7 kb of the FGFR3
gene upstream region was cloned into a luciferase plasmid to look
at promoter activity. We were unsuccessful in transfecting RT4
cells with plasmid DNA. In RT112 cells, both exposure to hypoxia
and treatment with 1mM DMOG led to significant luciferase
induction (Figure 2F), suggesting that this genomic region
conferred hypoxia-responsive transcriptional activity.
miR-100 expression is suppressed by hypoxia. We have
previously shown that FGFR3 is regulated by miR-100 expression
in bladder cancer (Catto et al, 2009). To determine whether
miR-100 may have a role in the hypoxic regulation of FGFR3
levels, miR-100 expression in RT4 cells after exposure to hypoxia
was examined. Exposure to hypoxia for 24 and 48 h led to a
significant decrease in miR-100 levels in RT4 (Figure 3A); miR-100
levels were unaffected by hypoxia in RT112, 97-7 and T24 cells
(Supplementary Figure 4). To better understand the effect of
hypoxia on miR-100 expression, its expression was also examined
in the immortalised, but otherwise relatively normal, bladder
urothelial line h-TERT; miR-100 levels were also suppressed by
hypoxia in these cells (Figure 3B). To confirm that suppression of
miR-100 was a specific outcome of hypoxia and not a general
consequence of repression of the miRNA machinery, the expres-
sion of the robust hypoxia-induced miRNA, miR-210, was
investigated. miR-210 was induced by hypoxia in all cell lines
investigated (Blick et.al, manuscript in preparation).
The hypoxic suppression of miR-100 could not be reversed by
knocking down either HIF-1a or HIF-2a (Figure 3C). We have
previously generated an in vivo hypoxia metagene signature that is
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Figure 3. Relationship between miR-100 expression and hypoxia. (A and B) Expression of miR-100 in (A) RT4 and (B) h-TERT cells exposed to
normoxia (white bars), 1% O2 (hatched bars) or 0.1% O2 (black bars) for the indicated time. (C) Expression of miR-100 in RT4 cells cultured in
normoxia (white bar) or 0.1% O2 (black bars) for 24 h after transfection with scramble (Scr) siRNA or siRNA against HIF-1a or HIF-2a. (D) Correlation
of miR-100 expression with the hypoxia score of 219 primary breast cancer samples. (A–C) Data are mean and s.e.m. of three independent
experiments. *Po0.05, **Po0.01, ***Po0.001.
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a robust indicator of tumour hypoxia (Winter et al, 2007; Buffa
et al, 2010). To examine the relationship between miR-100 and
hypoxia in vivo, we used our breast cancer tumour samples for
which both miRNA and mRNA expression profile data is available
(Buffa et al, 2011). In 219 breast cancer tumour samples, a
significant inverse correlation between miR-100 expression and
tumour hypoxia score was observed (Figure 3D).
It has previously been shown that the MYC oncogene
suppresses transcription from the miR-100 locus (Cairo et al,
2010). As FGFR3 signalling can activate MYC (Zingone et al,
2010), we investigated whether FGFR3 signalling in hypoxia
was responsible for reducing miR-100 levels. However, knocking
down FGFR3 levels in RT4 did not affect miR-100 levels (data not
shown).
miR-100 contributes to regulating FGFR3 levels in RT4
cells. The biological relevance of miR-100 on regulating FGFR3
expression in bladder cancer was investigated by perturbing
miR-100 levels in RT4 cells by transfecting either mimic-100 in
hypoxia (when miR-100 levels are low) or anti-miR-100 in
normoxia (when miR-100 levels are high). The transfection of
mimic-100 into RT4 cells modestly inhibited the hypoxic induction
of FGFR3 mRNA (Figure 4A) and strongly inhibited FGFR3
expression at the protein level (Figure 4B). Importantly, although
transfection of RT4 cells with anti-miR-100 in normoxia did not
increase FGFR3 mRNA levels (Figure 4C), FGFR3 protein levels
were increased after transfection of anti-miR-100 (Figure 4D).
Thus, levels of miR-100 have a role in regulating FGFR3 protein
levels in RT4 cells.
FGFR3 and miR-100 regulate cellular proliferation of RT4
cells. Activation of FGFR3 initiates signalling cascades in the cell
primarily mediated by the MAPK and PI3K cascades. Therefore,
the effects of FGFR3 and miR-100 on the activation of these
downstream pathways was investigated. Activation of MAPK
signalling ultimately leads to phosphorylation of the terminal
kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K
activation leads to the phosphorylation of PKB (Marshall et al,
2011). Transfection with siRNA against FGFR3 efficiently
decreased FGFR3 protein levels (Supplementary Figure 1). FGFR3
knockdown reduced phosphorylation of Ser473 on PKB (Figure 5A)
and the dual phosphorylation of Thr202/Tyr204 on MAPK
(Figure 5B). This effect was more prominent under hypoxic
conditions, where knockdown of FGFR3 led to an almost complete
loss of PKB and ERK phosphorylation. In hypoxia, transfection of
mimic-100 led to a modest decrease in phosphorylation of both
PKB and MAPK (Figures 5A and B). Transfection of anti-miR-100
in normoxia did not appreciably alter phosphorylation of MAPK
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(Supplementary Figure 5). Thus, increased levels of FGFR3 have an
important role in maintaining MAPK and PKB signalling in
hypoxia.
It is well established that MAPK and PKB activation are potent
mitogenic signals. Thus, the effects of miR-100 and FGFR3 on cell
viability was investigated. In 2-D growth, knockdown of FGFR3
reduced proliferation of RT4 cells in normoxia and hypoxia
(Figure 6A). In contrast, transfection of mimic-100 did not affect
the 2-D growth (Figure 6B). To assess the effects of FGFR3 and
miR-100 on 3-D growth, cells were grown as spheroids. FGFR3
knockdown significantly reduced the 3-D growth of RT4 cells
(Figures 6C and E). In addition, transfection of mimic-100 also
reduced spheroid volume of these cells (Figures 6D and F).
DISCUSSION
Hypoxia is an important aspect of tumour biology. It is known that
in addition to its effects on metabolic reprogramming, hypoxia can
lead to the activation of RTK signalling. HIF-1a directly targets the
C-MET receptor for transcriptional induction (Pennacchietti et al,
2003). Furthermore, HIF-2a has been implicated in increased
expression of the epidermal growth factor receptor by enhancing
translation (Franovic et al, 2007; Wang and Schneider, 2010). In
this study, we show for the first time that FGFR3 is induced by
hypoxia in bladder cancer cell lines. Thus, tumour hypoxia may
represent an additional mechanism for increased levels of FGFR3
in bladder cancer, and could be relevant in other tumours that have
been shown to express FGFR3 including head, neck (Marshall et al,
2011) and liver cancer (Gauglhofer et al, 2011).
The upregulation of FGFR3 is dependent on transcription as
mRNA levels were increased after exposure to both hypoxia and
the hypoxia-mimetic DMOG, and treatment with the transcription
inhibitor actinomycin D prevented the accumulation of FGFR3
protein after exposure to low oxygen. The increased expression of
FGFR3 was primarily dependent on HIF-1a, as knockdown of this
isoform of the a-subunit had a stronger effect on suppressing
FGFR3 levels in hypoxia. It should be noted that in these
experiments, the knockdown of HIF-2a was incomplete; thus,
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although FGFR3 levels were unaffected after knockdown, HIF-2a
may still have a role in regulating its expression in hypoxia.
Although the FGFR3 promoter region did confer hypoxic
transcriptional activity in a luciferase reporter assay, we have been
unable to immunoprecipitate any HREs in this genomic region.
Thus, either HREs exist in the region that we have not investigated
or the hypoxic induction of FGFR3 is dependent on other
transcription factors that act in syngergy/downstream of HIF.
The coordinated regulation of FGFR3 expression by additional
pathways warrants further investigation, as p73 and p63, members
of the p53 family of transcription factors, have been shown to
induce FGFR3 transcription (Sayan et al, 2010).
To further understand the potential mechanisms by which
FGFR3 levels may be increased under hypoxia, the role of miR-100
was explored. We have previously shown that miR-100 can target
FGFR3 and that the expression of these two molecules at the
mRNA levels were negatively correlated in the bladder cancer
(Catto et al, 2009). In both RT4 and h-TERT cells, hypoxia led to a
suppression of miR-100 levels. We do not have a data set of
matched miRNA and gene expression profiles available for bladder
cancer. Thus, we interrogated our breast cancer cohort for which
we have both miRNA (Buffa et al, 2011) and mRNA expresssion
data, and in which we have previously employed a hypoxia scoring
system to stratify tumours (Winter et al, 2007; Buffa et al, 2010).
Importantly, in vivo, the expression of miR-100 was anti-correlated
to tumour hypoxia in breast cancer, suggesting that the ability of
hypoxia to decrease miR-100 levels extends to other tumour types.
The mechanism of downregulation of hypoxia-regulated genes,
including miRNAs, is unclear. It is thought that the majority of
genes downregulated by hypoxia are not direct targets of HIF
(Mole et al, 2009). Indeed, the hypoxic suppression of miR-100
could not be reserved by knockdown of either HIF-1a or HIF-2a.
Although the majority of cellular responses to hypoxia are
mediated by HIF, a number of HIF-independent events in hypoxia
have been reported, including the induction of haeme oxygenase-1
in Chinese hamster ovary cells (Wiesener et al, 1998; Wood et al,
1998) and ICAM-1 in monocytes (Winning et al, 2010). It is likely
that one of the other stress–response pathways is responsible for
regulating the expression of a subset of genes under hypoxia
(Koumenis and Wouters, 2006).
In RT4 cells, miR-100 expression contributes to the regulation
of FGFR3 levels, as transfection of anti-miR-100 increased FGFR3
levels in normoxia and introduction of mimic-100 decreased
FGFR3 levels in hypoxia. As the suppression of miR-100 was not
dependent on the HIF-a subunits, yet hypoxic induction of FGFR3
could be reversed by HIF-1a knockdown, we conclude that two
parallel mechanisms operate to maintain increased FGFR3 levels in
hypoxia. Of the two, the HIF-1a-dependent pathway is likely to
have the central role, with the suppression of miR-100 serving to
augment increased FGFR3 levels. The ability to circumvent
miRNA-mediated regulation of gene expression can be advanta-
geous to cells. Indeed, it has recently been shown that in
glioblastoma, a duplication of chromosome 4p16.3 generates a
FGFR3-TAAC3 fusion protein in which the 30 UTR of FGFR3 is
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lost. The fusion protein is insensitive to regulation by the miR-99, a
member of the miR-100 family, resulting in increased expression of
the aberrant protein and enhanced tumour growth in xenografts
models (Parker et al, 2013).
Functionally, FGFR3 and miR-100 are responsible for regulating
cell proliferation of RT4 cells. Of note is the observation that
knocking down FGFR3 expression in RT4 cells led to a dramatic
decrease in cell viability in normoxia and hypoxia, concomitant with
a decrease in the activation of PKB and MAPK signalling. Thus, even
in cells expressing the FGFR3 without a point mutation, autocrine
and/or paracrine signalling clearly have an indispensible role in cell
viability. We found knockdown of FGFR3 had a more dramatic effect
on reducing the phosphorylation of MAPK and PKB in cells exposed
to hypoxia compared with their normoxic counterparts. This strongly
suggests that increased levels of FGFR3 has a crucial role in
maintaining the viability of RT4 cells exposed to hypoxia.
The role of miR-100 was found to be more subtle, with a
decrease in cell viability observed in 3-D cultures but not 2-D
growth. Thus, the role of miR-100 is more pronounced in stressful
cellular conditions, when nutrient supply is perhaps more limiting
and oxygen gradients are steeper. A single miRNA is likely to
regulate the expression of multiple target genes, although the effect
on each may be subtle (Selbach et al, 2008). Indeed, it has recently
been reported that miR-100 can target mTOR (Nagaraja et al,
2010). Under more severe conditions of 3-D growth, miR-100 is
likely to have a role in regulating cell proliferation by targeting
additional pathways, such as mTOR, which has a key role during
stress (Tickoo et al, 2011).
In summary, we have shown for the first time that hypoxic
regulation of FGFR3 occurs at the transcriptional level but is also
partly dependent on suppression of miR-100 expression. This
represents a novel mechanism for regulating FGFR3 in bladder
cancer that may provide an additional mechanism for increased
expression of this growth-promoting pathway that could con-
tribute to the pathogenesis of this disease. The link with hypoxia
may explain the strong association with the papillary phenotype,
where it has been shown that the luminal cells away from the
vascular core are hypoxic. This may provide selection for
upregulation of FGFR3 and maintenance of the papillary
phenotype. FGFR3 overexpression may provide a positive effect
by preventing progression to MI disease; the loss of this potentially
protective mechanism requires additional studies. However, the
clear effect of FGFR3 on signalling and growth under hypoxia also
suggests a potential synthetic lethal approach, targeting the hypoxic
cells away from the vascular core.
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